Novel glucose-lowering agents that benefit diabetic foot: icing on the cake
The prevalence of diabetes mellitus is increasing and is linked to several complications, including diabetic foot. Novel glucose-lowering agents are sought that also have beneficial effects in reducing diabetic complications. Among the novel glucose-lowering agents demonstrating clinical promise, th...
Saved in:
| Main Authors: | Qin Li, Shiyan Yu, Shunli Rui, Xiaobu Lin, Yi Yuan, David G. Armstrong, Yi Xu, Wuquan Deng |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2025.1581403/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparison of New‐Onset Peripheral Artery Disease in Patients With Type 2 Diabetes Exposed to Sodium–Glucose Cotransporter‐2 Inhibitors, Dipeptidyl Peptidase‐4 Inhibitors, or Glucagon‐Like Peptide‐1 Agonists: A Population‐Based Cohort Study
by: Oscar Hou‐In Chou, et al.
Published: (2025-06-01) -
Effects of switching from dipeptidyl peptidase 4 inhibitors to oral semaglutide on oxidative stress and glycemic variability in patients with type 2 diabetes: an open-label, prospective, randomized, multicenter, parallel-group comparison study
by: Makoto Ohara, et al.
Published: (2025-04-01) -
Comparative risk of cancer associated with SGLT inhibitors and DPP-4 inhibitors in patients with diabetes: a systematic review and meta-analysis
by: Hamed Hajishah, et al.
Published: (2025-08-01) -
The impacts of SGLT2 inhibitors on the mortality of patients with tuberculosis
by: Chung-Shu Lee, et al.
Published: (2025-05-01) -
Association of sodium-glucose cotransporter-2 inhibitor use and mortality in patients with endometrial cancer: a retrospective cohort study
by: Min Wang, et al.
Published: (2025-07-01)